Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).
ANALYSIS/QUANTITATION OF BONE
BIOCHEMICAL MARKERS OF BONE TURNOVER
BONE MODELING AND REMODELING
DXA
OSTEOPOROSIS
Journal
JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
09
12
2021
accepted:
26
01
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
Previous subgroup analyses from the ACTIVE trial in women with postmenopausal osteoporosis (NCT01343004) using three-dimensional (3D)-processing of dual X-ray absorptiometry (DXA) scans indicated greater increases in total hip cortical volumetric bone mineral density (Ct.vBMD) and estimated indices of hip strength following 18 months of abaloparatide (ABL) versus placebo or teriparatide. The current post hoc analyses describe hip 3D-DXA data for ACTIVExtend (NCT01657162), in which 18 months of ABL followed by 24 months of alendronate (ABL/ALN) increased hip and spine areal BMD (aBMD) and reduced fracture risk versus placebo (PBO) followed by ALN (PBO/ALN). In an ACTIVExtend subgroup (ABL/ALN,
Identifiants
pubmed: 35434451
doi: 10.1002/jbm4.10612
pii: JBM410612
pmc: PMC9009108
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10612Informations de copyright
© 2022 Radius Health, Inc. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Déclaration de conflit d'intérêts
RW and LH are employees of Galgo Medical and paid consultants of Radius Health, Inc.; LH is a shareholder of Galgo Medical. PJK, JB, and YW are employees and shareholders of Radius Health, Inc.
Références
Endocr Pract. 2020 May;26(5):564-570
pubmed: 32427525
IEEE Trans Med Imaging. 2017 Jan;36(1):27-39
pubmed: 27448343
Bone. 2001 Dec;29(6):511-6
pubmed: 11728920
Clin Pharmacokinet. 2005;44(6):551-70
pubmed: 15932344
J Orthop Surg Res. 2019 Dec 11;14(1):432
pubmed: 31829214
Endocr Pract. 2021 Sep;27(9):941-947
pubmed: 34111556
Med Phys. 2016 Apr;43(4):1945
pubmed: 27036590
J Clin Endocrinol Metab. 2000 Jun;85(6):2129-34
pubmed: 10852440
Indian J Orthop. 2020 Jan 31;54(4):454-462
pubmed: 32549960
Osteoporos Int. 2008 Apr;19(4):399-428
pubmed: 18266020
J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957
pubmed: 29800372
JAMA. 2016 Aug 16;316(7):722-33
pubmed: 27533157
J Clin Densitom. 2018 Oct - Dec;21(4):550-562
pubmed: 28624339
Endocrinol Metab Clin North Am. 2021 Jun;50(2):179-191
pubmed: 34023037
J Orthop Surg (Hong Kong). 2014 Apr;22(1):92-5
pubmed: 24781623
J Bone Miner Res. 2017 Feb;32(2):198-202
pubmed: 27925287
N Engl J Med. 2005 Aug 11;353(6):555-65
pubmed: 16093464
Bone. 2007 Nov;41(5):804-12
pubmed: 17825637
J Bone Miner Res. 2010 May;25(5):960-7
pubmed: 19929434
J Bone Miner Res. 2009 Apr;24(4):726-36
pubmed: 19049337
Osteoporos Int. 2019 Mar;30(3):667-673
pubmed: 30635696
J Bone Miner Res. 2018 Aug;33(8):1397-1406
pubmed: 29694685
J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7
pubmed: 16636120
Osteoporos Int. 2021 Mar;32(3):575-583
pubmed: 33496831
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457